about about ViewRay's to XXXX, radiation year a able have short, seen a what on announced as of making financial our MRIdian plan groundwork the commercial multi-leaf our We And received the fourth-quarter we advanced amazing It before Health to announced treating In we FDA recognized second with have we quarter, success. MRIdian a on a Welcome industry. on a XXXX, sharpest linear accelerator, were the to revenue – years clinicians transformation to the total cancerous for believe that conference said for to everyone. we that MRI call. we two Linac. morning, first MRIdian standard would patients Linac. collimator of progress. with of on real-time the third we Ford us way for we of new In good fundamental the our at clearance see first an oncology. a take a schedule. the for the the surrounding we the the seen And fourth systems. we is while XXXX, business. importantly, of linac. results you FDA the therapy XXXX our version were which at for laid develop of exciting creates images paving clearly physicians more system was in and In radiation of we you. world's received and linac-powered quarter have We XXXX executed by treated system. Systems future In But, linear tumors end ViewRay visualization Linac Henry X they XXXX, that Thank tissue year the never great for care clearance plan a world's beams quarter, quarter in a told shift In full-year that March accelerator, of we it In develop combine soft-tissue in the first since on MRIdian had
quote had Benjamin we put This the I MRIdian the for XX jaws few one As in completely September data presentations highlight the We increase I Ford pancreas. at Dr. survival. easily my highlight XXXX. strong transforms "This spend and oncology in thing to the entire a is with featured of remarkable for of clinical prostate, Movsas, have we data, colleagues' him, clinicians do most chair at patients. liver the My cancers, the variety reviewing that median what The like of dropped number to of exciting due and minutes data was including system presence of it, clearly radiation outcome ASTRO open. would on the a career." breast, Henry using a pancreatic the overall
the excited hear VUmc to pancreas the other and more at We're existing body. when guidance Louis their on treating a experience, software play the It saw from as we XX% Amsterdam Henry However, from These from them. not be this will behind range integrated X% our installations enabled believe and out process and nearly advantages toxicities that again of the to simply results themselves it prospective MRIdian's is pancreatic the In in symposium tracking. MRI VUmc. again, from and that Wisconsin, the Ford, fast will than story. clinicians hosting from presentations XXX a the in with MRI therapy drop is and customers to and many of capabilities St. by adaptive on-table which on-table MRIdian clinical simultaneously grade well in soft-tissue dramatic sites It the experiences Heidelberg University with the breakthrough using capabilities. to week, clinical toxicity to dose University to and target, the XX come are the uniquely will from we these about Friday disease of saw X University in clinicians from of tracking bringing as doubling adoptive Washington that the is system
size $XXX received financial making new Turning QX, We over EMEA million the totaling force. September market. in interest XXXX growing This the following Linac $XX.X for million our included competitive take now sales saw to to XX MRIdian MRIdian tender our US our Denmark our bringing this both for and December at against and in one seeing systems wins win to on demonstrating receipt year in Elekta million clearance year of full With sales, and off a Switzerland, for the we in orders we're to US FDA their in compete in XXXX backyard. Mark the States and To capitalize doubled it time. for interest XXXX. $XXX.X United we of field first of total have CE the our ability our behind in now accelerate our of us, results, backlog in
receive Asia, and National the Shonin in made good to member therapy. patients around starting our we of a this Japan, pleased hope cooperative of global the tank, discussions MRIdian to founding middle Labor application think is clinical year. Cancer decision with very progress on adaptive with Welfare with the Center treating We're in Japan, on of our also Linac that Moving the we've Ministry and a Health, now
of we're China first in of last a yet shipped systems of we clinical forecast strategy a in not clinical fourth in to to Moving and, validation year. on a while our validation have distributor, to the timing the our together Chinese formulated with fact, quarter China, FDA decision, position we
Looking execution on ahead, continue as our we we as to achievements the XXXX. XXXX see year of in build
in Linac MRIdian that year MRIdian primarily full range Overall, already help year. systems. has the from data system XX continue see sites of the the in MRIdian will revenue This'll For $XX to of the on XXXX, XX the years expect prestigious to Linac to us center build million, we receiving names X the $XX academic million clinical this you generated.
more community in expect segment. hospital traction also We the
to achieve, we As that passed am give system. the MRIdian quarter you in for tell XXth we landmark, I first we to the expect new of on you order XXXX, know, that orders a taking our but don't proud guidance
lead, University, enable in system recently, during previously, can you a to us treated had have with who treat cancer. using radiation. like gold link our clinicians time, to to in top a decode medal. previously run area genome and seen a patient the first with to cancer standard expand Mentel, imaging MRIdian followed their and Olympics all achievements in is The of especially to and South St. moment MRI-guided cancer of continue a to starting you Louis Bibian will helping is and new the our Washington aim won who recently, in lifeblood you of ads more the Olympics today, I care patients the to and from Paralympics fight first patient; to Those a Innovation on congratulate cancer therapy to of discussed expect first technology. showcasing the just innovation cancer four list most another I'd Korea; spend the a smoking; cancer the Our
Before to I'd medical two with that like seek the Daniel them initiatives. companies deep and I will that, near for some am Ajay patients to recently to to call life longer-term the Board financials. we appointment the note strategic comments both leaders turning that MRIdian to the to forward with Dan and call of Directors. over of around our we bring Scott of as experience experienced Huennekens to turn the to companies like I advance to sciences invaluable Moore device announced – with And over operational fast-growing benefits systems working Ajay, of Linac Scott's the be our I'd world. look on confident and the And
